Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al
- PMID: 33549765
- PMCID: PMC7862016
- DOI: 10.1016/j.cmi.2021.01.025
Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al
Figures
Comment on
-
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8. Clin Microbiol Infect. 2021. PMID: 33705848 Free PMC article. No abstract available.
-
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27. Clin Microbiol Infect. 2021. PMID: 33915284 Free PMC article.
References
-
- NHS patients to receive life-saving COVID-19 treatments that could cut hospital time by 10 days-GOV.UK n.d. https://www.gov.uk/government/news/nhs-patients-to-receive-life-saving-c... (accessed 9 January 2021).
-
- Rambaut A., Loman N., Pybus O., Barclay W., Barrett J., Carabelli A. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations—SARS-CoV-2 coronavirus/nCoV-2019 Genomic Epidemiology—Virological. https://virological.org/t/preliminary-genomic-characterisation-of-an-eme... n.d.
-
- European Centre for Disease Prevention and Control . 2020. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
